Inflammatory disorders in IDH-mutated myeloid neoplasms: Characteristics and response to IDH inhibitors.
Stammler R, Chen P, Debeaupuis O, Zhao LP, Ruyer-Thompson M, Zakine E, Rossignol J, Goldwirt L, Comont T, Heiblig M, Adès L, Sebert M, Allain JS, Campagne J, Couturier MA, Cumin M, Dalmas MC, Denis G, Devloo C, De Voeght A, Drevon L, Duffau P, Georgin-Lavialle S, Gobert D, Kosmider O, Rieux-Laucat F, Abisror N, Lazaro E, Lopez JG, Maria A, Mauhin W, Merindol J, Merlot C, Mirault T, Pascal L, Perrin F, Raffoux E, Rahme R, Roos-Weil D, Terrier B, Thoreau B, Fain O, Fenaux P, Hirsch P, Jachiet V, Hadjadj J, Mékinian A; MINHEMON.
Stammler R, et al. Among authors: allain js.
Hemasphere. 2025 Nov 25;9(11):e70256. doi: 10.1002/hem3.70256. eCollection 2025 Nov.
Hemasphere. 2025.
PMID: 41306328
Free PMC article.
No abstract available.